// App-Quantinova.ai

52 : The Addition of Navitoclax to Ruxolitinib Demonstrates Efficacy within Different High-Risk Populations in Patients with Relapsed/Refractory Myelofibrosis

Researchers

Presenter

  • Naveen Pemmaraju

Principal Investigators

  • Jacqueline S. Garcia

  • Jalaja Potluri

  • Leanne Holes

  • Jason Harb

  • Paul Jung

  • Jessica E. Hutti

  • Josef T. Prchal

  • Srdan Verstovsek

  • Claire Harrison

Medical Centers

  • Department of Bioinformatics, The University of Texas MD Anderson Cancer Center, Houston, TX

  • Department of Medical Oncology, Dana Farber Cancer Institute, Boston, MA

  • AbbVie, Inc., North Chicago, IL

  • Division of Hematology and Hematologic Malignancies, Huntsman Cancer Institute, University of Utah, Salt Lake City, UT

  • Department of Haematology, Guys and St Thomas Hospitals NHS Trust, London, United Kingdom

Locations

  • United States

  • United Kingdom

Companies

  • N/A

Study Components

Therapeutic Area

  • Oncology (ONC)

Disease

  • Myelofibrosis

Biomarkers

  • N/A

Drug/Treatment

  • Ruxolitinib phosphate

  • Navitoclax

Outcome

  • N/A

Study Design

  • N/A

Phase

  • II

Study Id's

  • NCT03222609

Sponsors

  • N/A

Result

  • N/A

Copyright © 2026. QuantiNova All rights reserved